2-bromo-1-[(S)-2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-pyrrolidine-1-yl]-ethanone | 851028-74-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-[(S)-2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-pyrrolidine-1-yl]-ethanone
• 英文别名: 2-bromo-1-[(2S)-2-(5-tert-butyl-1,3,4-oxadiazole-2-carbonyl)pyrrolidin-1-yl]ethanone
• CAS: 851028-74-5
• 化学式: C₁₃H₁₈BrN₃O₃
• 分子量: 344.208
• InChiKey: IFFZKVSTHYDZCJ-QMMMGPOBSA-N

物化性质

• 沸点：
  478.0±55.0 °C(Predicted)
• 密度：
  1.451±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  76.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-bromo-1-[(S)-2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-pyrrolidine-1-yl]-ethanone 、 叔丁胺 在 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 生成 2-tert-butylamino-1-[(S)-2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-pyrrolidine-1-yl]-ethanone
  参考文献：
  名称：

  Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: Oxadiazolyl ketones

  摘要：

  Synthesis of a novel series of DPPIV inhibitors with 1,2,4- and 1,3,4-oxadiazolyl ketone derivatives and its structure-activity relationships are discussed. Compound 18h showed good inhibitory activity against DPPIV and favorable pharmacokinetic properties. In vivo pharmacodynamic efficacy and co-crystal structure of compound 18h with DPPIV is also described. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.046
• 作为产物：
  描述：

  Boc-L-脯氨酸甲酯 在 盐酸 、 lithium hydroxide 、 正丁基锂 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 magnesium bromide 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-bromo-1-[(S)-2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-pyrrolidine-1-yl]-ethanone
  参考文献：
  名称：

  Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: Oxadiazolyl ketones

  摘要：

  Synthesis of a novel series of DPPIV inhibitors with 1,2,4- and 1,3,4-oxadiazolyl ketone derivatives and its structure-activity relationships are discussed. Compound 18h showed good inhibitory activity against DPPIV and favorable pharmacokinetic properties. In vivo pharmacodynamic efficacy and co-crystal structure of compound 18h with DPPIV is also described. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.046

文献信息

• [EN] NOVEL INHIBITORS OF DPP-IV, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT<br/>[FR] INHIBITEURS DE DPP-IV, PROCEDES D'ELABORATION CORRESPONDANTS, ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CES INHIBITEURS COMME PRINCIPE ACTIF
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005037828A1

  公开（公告）日：2005-04-28

  The present invention relates to pyrrolidine-based compounds of novel structure exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV, as defined in Formula 1 of the specification, and methods of preparing the same and pharmaceutical compositions containing the same as an active agent.

  本发明涉及一种具有新结构的吡咯烷基化合物，其表现出良好的抑制二肽基肽酶-IV活性，如规范中的公式1所定义的那样，以及制备该化合物的方法和含有该化合物作为活性剂的药物组合物。
• Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: Oxadiazolyl ketones
  作者：Ki Dong Koo、Min Jung Kim、Sungsub Kim、Kyoung-Hee Kim、Sang Yong Hong、Gwong-Cheung Hur、Hyeon Joo Yim、Geun Tae Kim、Hee Oon Han、O Hwan Kwon、Tae Sik Kwon、Jong Sung Koh、Chang-Seok Lee

  DOI：10.1016/j.bmcl.2007.05.046

  日期：2007.8

  Synthesis of a novel series of DPPIV inhibitors with 1,2,4- and 1,3,4-oxadiazolyl ketone derivatives and its structure-activity relationships are discussed. Compound 18h showed good inhibitory activity against DPPIV and favorable pharmacokinetic properties. In vivo pharmacodynamic efficacy and co-crystal structure of compound 18h with DPPIV is also described. (c) 2007 Elsevier Ltd. All rights reserved.